I don't "think" it should go to a 60% haircut, BUT, it's plausible (unfortunately) simply due to the fact some investors might get the thought in their mind that Ridaforolimus has no future and once again Ariad is a "one drug" company. Obviously false assumptions, however, the market has a way of over-reacting, and this stock is not loved by Wall Street.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.